BBIO · CIK 0001743881
What BridgeBio Pharma, Inc. told the SEC could break it.
BridgeBio's disclosures cluster on concentration and policy exposure typical of a commercial biopharma. Its revenue leans on a few buyers — two customers were about 14.5% and 11.1% of revenue — concentrating receivables and product sales. It owns no manufacturing and relies on a single-source contract manufacturer for certain product candidates, so an interruption in active-ingredient or formulated-drug supply would hit its commercial product and pipeline. Because most of its revenue comes from US sales, it is also exposed to drug-pricing reform, notably CMS's proposed GLOBE model, which would make sole-source biologics pay incremental Medicare Part B rebates tied to international benchmark prices.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- two customers (14.5% / 11.1%)medium
Two individual customers accounted for ~14.5% and ~11.1% of BridgeBio's revenue (anonymized as Customer D and Customer E), concentrating receivables and product-sale revenue.
“Customer D 14.5 % * * Customer E 11.1 % * * * Represents less than 10% and/or not a customer in the applicable period.”
SEC filing →As of 2026
Regulatory & policy
- US drug-pricing reform (CMS GLOBE Part B benchmark rebates, MFN reference pricing)medium
BridgeBio (which earns most revenue from U.S. sales) is exposed to U.S. drug-pricing reform — the CMS-proposed GLOBE model would require sole-source biologics to pay incremental Medicare Part B rebates tied to international benchmark prices, alongside MFN reference-pricing rebate risk.
“on December 19, 2025, CMS proposed the Global Benchmark for Efficient Drug Pricing Model (“GLOBE”) for Medicare Part B, would require manufacturers of specified single source drugs and sole source biologics to pay incremental rebates based on international benchmark prices, with participation triggered for products meeting CMS's spending and eligibility criteria.”
SEC filing →As of 2026
Sole-source dependency
- single-source contract manufacturer (API & formulated drugs)medium
BridgeBio does not own or operate manufacturing and relies on a single-source manufacturer for certain product candidates; an interruption in supply of active pharmaceutical ingredients and formulated drugs would hurt its commercial product and pipeline.
“For certain clinical product candidates, we rely on a single source manufacturer.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
Bayer AG
“Outside the United States, acoramidis is marketed as Beyonttra™ and is commercialized through strategic collaboration partners, including Bayer in Europe and Alexion in Japan, as well as directly by BridgeBio in certain international markets.”
Cited →Alexion Pharma International Operations Ltd. (AstraZeneca)
“Eidos is also a party to a license agreement with Alexion Pharma International Operations Limited Company (“Alexion”) pursuant to which we depend on Alexion for the commercialization of Beyonttra in Japan;”
Cited →Kyowa Kirin Co., Ltd.
“QED is party to an exclusive license with Kyowa Kirin to develop, manufacture, and commercialize infigratinib for achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch